{"id":745444,"date":"2017-12-06T17:02:00","date_gmt":"2017-12-06T17:02:00","guid":{"rendered":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/new-england-journal-of-medicine-publishes-phase-3-clinical-study-of-prevymis-letermovir-mercks-new-cmv-prophylaxis-medicine\/"},"modified":"2025-11-07T01:26:07","modified_gmt":"2025-11-07T06:26:07","slug":"new-england-journal-of-medicine-publishes-phase-3-clinical-study-of-prevymis-letermovir-mercks-new-cmv-prophylaxis-medicine","status":"publish","type":"news_item","link":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/new-england-journal-of-medicine-publishes-phase-3-clinical-study-of-prevymis-letermovir-mercks-new-cmv-prophylaxis-medicine\/","title":{"rendered":"New England Journal of Medicine Publishes Phase 3 Clinical Study of PREVYMIS\u2122 (letermovir), Merck\u2019s New CMV Prophylaxis Medicine"},"content":{"rendered":"<p>\n      Merck &amp; Co., Inc. (NYSE: MRK), known as MSD outside the United States<br \/>\n      and Canada, today announced that the <i>New England Journal of Medicine<\/i><br \/>\n      has published online the main results from the pivotal Phase 3 clinical<br \/>\n      study of PREVYMIS\u2122 (letermovir), the company\u2019s new medicine for<br \/>\n      prophylaxis (prevention) of cytomegalovirus (CMV) infection and disease<br \/>\n      in adult CMV-seropositive recipients [R+] of an allogeneic hematopoietic<br \/>\n      stem cell transplant (HSCT). The paper will also appear in a forthcoming<br \/>\n      print issue of the journal.\n    <\/p>\n<p>\n      CMV-seropositive patients who undergo allogeneic hematopoietic-cell<br \/>\n      transplantation are at high risk for CMV reactivation. CMV infection is<br \/>\n      a common clinically significant complication in these patients and early<br \/>\n      CMV reactivation after transplant is associated with increased<br \/>\n      mortality. PREVYMIS is a first-in-class antiviral drug that inhibits CMV<br \/>\n      replication.\n    <\/p>\n<p>\n      \u201cThis study culminates more than a decade of efforts to identify new,<br \/>\n      highly effective antiviral medicines for patients that can be prescribed<br \/>\n      prophylactically after hematopoietic-cell transplantation,\u201d said Dr.<br \/>\n      Francisco M. Marty, associate professor of medicine at Harvard Medical<br \/>\n      School and attending physician in transplant and oncology infectious<br \/>\n      diseases at Dana-Farber Cancer Institute and Brigham and Women\u2019s<br \/>\n      Hospital.\n    <\/p>\n<p>\n      In the study, significantly fewer patients in the PREVYMIS arm (37.5%,<br \/>\n      n=122\/325) compared to the placebo arm (60.6%, n=103\/170) developed<br \/>\n      clinically significant CMV infection, discontinued treatment or had<br \/>\n      missing data through Week 24 post-transplant (p&lt;0.001), the primary<br \/>\n      efficacy endpoint. The treatment effect for PREVYMIS in preventing<br \/>\n      clinically significant CMV infection was consistent across pre-specified<br \/>\n      high- and low-risk strata for CMV reactivation both at Week 14 (end of<br \/>\n      treatment) and at Week 24 post-transplant. All-cause mortality in<br \/>\n      patients receiving PREVYMIS was lower compared to placebo at Week 24<br \/>\n      post-transplant and at Week 48 post-transplant.\n    <\/p>\n<p>\n      PREVYMIS is contraindicated in patients receiving pimozide or ergot<br \/>\n      alkaloids. Increased pimozide concentrations may lead to QT prolongation<br \/>\n      and torsades de pointes. Increased ergot alkaloids concentrations may<br \/>\n      lead to ergotism. PREVYMIS is contraindicated with pitavastatin and<br \/>\n      simvastatin when co-administered with cyclosporine. Significantly<br \/>\n      increased pitavastatin or simvastatin concentrations may lead to<br \/>\n      myopathy or rhabdomyolysis.\n    <\/p>\n<p>\n      \u201cMerck has been working to bring PREVYMIS forward to address the<br \/>\n      significant unmet medical need for hematopoietic stem cell transplant<br \/>\n      recipients \u2013 a vulnerable patient population at risk from CMV infection<br \/>\n      and disease,\u201d said Dr. Nicholas Kartsonis, vice president, infectious<br \/>\n      disease clinical research, Merck Research Laboratories. \u201cBased on the<br \/>\n      results of this study, in addition to the recent U.S. approval of<br \/>\n      PREVYMIS, Merck has regulatory applications pending in other markets,<br \/>\n      including in the European Union and Japan.\u201d\n    <\/p>\n<p>\n      PREVYMIS will be available for order in the U.S. in early December.\n    <\/p>\n<p>\n      This double-blind study randomized adult CMV-seropositive allogeneic<br \/>\n      hematopoietic-cell transplant recipients to receive PREVYMIS or placebo<br \/>\n      orally or intravenously through Week 14 post-transplant. PREVYMIS was<br \/>\n      dosed at 480 mg\/day (or 240 mg\/day when co-administered with<br \/>\n      cyclosporine). Patients who developed clinically-significant CMV<br \/>\n      infection, defined as CMV disease or CMV viremia requiring preemptive<br \/>\n      treatment, discontinued study drug and received anti-CMV treatment. All<br \/>\n      patients in the study were followed through Week 48 post-transplant.\n    <\/p>\n<p>\n      Key prespecified secondary endpoints of the study were the proportion of<br \/>\n      patients with clinically-significant CMV infection through Week 14 and<br \/>\n      the time to clinically-significant CMV infection in the primary efficacy<br \/>\n      population. All treated patients were included in the safety analyses.<br \/>\n      Prespecified exploratory endpoints of the study included cumulative<br \/>\n      all-cause mortality, time to engraftment, and the incidence of<br \/>\n      graft-versus-host disease or non-CMV infections.\n    <\/p>\n<p>\n      <b>Additional Selected Safety Information about PREVYMIS (letermovir)<\/b>\n    <\/p>\n<p>\n      The concomitant use of PREVYMIS and certain drugs may result in<br \/>\n      potentially significant drug interactions, some of which may lead to<br \/>\n      adverse reactions (PREVYMIS or concomitant drugs) or reduced therapeutic<br \/>\n      effect of PREVYMIS or the concomitant drug. Consider the potential for<br \/>\n      drug interactions prior to and during PREVYMIS therapy; review<br \/>\n      concomitant medications during PREVYMIS therapy; and monitor for adverse<br \/>\n      reactions associated with PREVYMIS and concomitant medications.\n    <\/p>\n<p>\n      The cardiac adverse event rate (regardless of investigator-assessed<br \/>\n      causality) was higher in patients receiving PREVYMIS than placebo (13%<br \/>\n      vs. 6%). The most common cardiac adverse events were tachycardia<br \/>\n      (reported in 4% PREVYMIS patients and 2% placebo patients) and atrial<br \/>\n      fibrillation (reported in 3% PREVYMIS patients and 1% placebo patients).<br \/>\n      These adverse events were reported as mild or moderate in severity.\n    <\/p>\n<p>\n      The rate of adverse events occurring in at least 10% of PREVYMIS-treated<br \/>\n      HSCT recipients and at a frequency at least 2% greater than placebo were<br \/>\n      nausea (27% vs. 23%), diarrhea (26% vs. 24%), vomiting (19% vs. 14%),<br \/>\n      peripheral edema (14% vs. 9%), cough (14% vs. 10%), headache (14% vs.<br \/>\n      9%), fatigue (13% vs. 11%), and abdominal pain (12% vs. 9%).\n    <\/p>\n<p>\n      The most frequently reported adverse event that led to study drug<br \/>\n      discontinuation was nausea (occurring in 2% of PREVYMIS patients and 1%<br \/>\n      of placebo patients). Hypersensitivity reaction, with associated<br \/>\n      moderate dyspnea, occurred in one patient following the first infusion<br \/>\n      of IV PREVYMIS after switching from oral PREVYMIS, leading to treatment<br \/>\n      discontinuation.\n    <\/p>\n<p>\n      Co-administration of PREVYMIS (letermovir) with drugs that are<br \/>\n      inhibitors of organic anion-transporting polypeptide 1B1\/3 (OATP1B1\/3)<br \/>\n      transporters may result in increases in letermovir plasma concentrations.\n    <\/p>\n<p>\n      Co-administration of PREVYMIS with midazolam results in increased<br \/>\n      midazolam plasma concentration. Co-administration of PREVYMIS with drugs<br \/>\n      that are CYP3A substrates may result in clinically relevant increases in<br \/>\n      the plasma concentrations of co-administered CYP3A substrates.\n    <\/p>\n<p>\n      Co-administration of PREVYMIS with drugs that are substrates of<br \/>\n      OATP1B1\/3 transporters may result in a clinically relevant increase in<br \/>\n      plasma concentrations of co-administered OATP1B1\/3 substrates.\n    <\/p>\n<p>\n      The magnitude of CYP3A- and OATP1B1\/3-mediated drug interactions on<br \/>\n      co-administered drugs may be different when PREVYMIS is co-administered<br \/>\n      with cyclosporine. See the prescribing information for cyclosporine for<br \/>\n      information on drug interactions with cyclosporine.\n    <\/p>\n<p>\n      If dose adjustments of concomitant medications are made due to treatment<br \/>\n      with PREVYMIS, doses should be readjusted after PREVYMIS treatment is<br \/>\n      completed.\n    <\/p>\n<p>\n      Established or potentially clinically significant drug interactions may<br \/>\n      occur with co-administration of PREVYMIS and drug\/drug classes,<br \/>\n      including, but not limited to, the following:\n    <\/p>\n<ul>\n<li class=\"bwlistitemmargb\">\n        Anti-arrhythmic agents<\/p>\n<ul>\n<li class=\"bwlistitemmargb\">\n            Amiodarone: increases amiodarone concentration\n          <\/li>\n<\/ul>\n<\/li>\n<li class=\"bwlistitemmargb\">\n        Anticoagulants<\/p>\n<ul>\n<li class=\"bwlistitemmargb\">\n            Warfarin: decreases warfarin concentration\n          <\/li>\n<\/ul>\n<\/li>\n<li class=\"bwlistitemmargb\">\n        Anticonvulsants<\/p>\n<ul>\n<li class=\"bwlistitemmargb\">\n            Phenytoin: decreases phenytoin concentration\n          <\/li>\n<\/ul>\n<\/li>\n<li class=\"bwlistitemmargb\">\n        Antidiabetic agents<\/p>\n<ul>\n<li class=\"bwlistitemmargb\">\n            Glyburide: increases glyburide concentration\n          <\/li>\n<li class=\"bwlistitemmargb\">\n            Repaglinide: increases repaglinide concentration\n          <\/li>\n<li class=\"bwlistitemmargb\">\n            Rosiglitazone: increases rosiglitazone concentration\n          <\/li>\n<\/ul>\n<\/li>\n<li class=\"bwlistitemmargb\">\n        Antifungals<\/p>\n<ul>\n<li class=\"bwlistitemmargb\">\n            Voriconazole: decreases voriconazole concentration\n          <\/li>\n<\/ul>\n<\/li>\n<li class=\"bwlistitemmargb\">\n        Antimycobacterial<\/p>\n<ul>\n<li class=\"bwlistitemmargb\">\n            Rifampin: decreases letermovir concentration\n          <\/li>\n<\/ul>\n<\/li>\n<li class=\"bwlistitemmargb\">\n        Antipsychotics<\/p>\n<ul>\n<li class=\"bwlistitemmargb\">\n            Pimozide: increases pimozide concentration; co-administration is<br \/>\n            contraindicated\n          <\/li>\n<\/ul>\n<\/li>\n<li class=\"bwlistitemmargb\">\n        Ergot alkaloids<\/p>\n<ul>\n<li class=\"bwlistitemmargb\">\n            Ergotamine: increases ergotamine concentration; co-administration<br \/>\n            is contraindicated\n          <\/li>\n<li class=\"bwlistitemmargb\">\n            Dihydroergotamine: increases dihydroergotamine concentration;<br \/>\n            co-administration is contraindicated\n          <\/li>\n<\/ul>\n<\/li>\n<li class=\"bwlistitemmargb\">\n        HMG-CoA reductase inhibitors<\/p>\n<ul>\n<li class=\"bwlistitemmargb\">\n            Pitavastatin, Simvastatin: increases HMG-CoA reductase inhibitors<br \/>\n            concentration; co-administration is contraindicated when PREVYMIS<br \/>\n            is co-administered with cyclosporine\n          <\/li>\n<li class=\"bwlistitemmargb\">\n            Atorvastatin: increases atorvastatin concentration\n          <\/li>\n<li class=\"bwlistitemmargb\">\n            Fluvastatin, Lovastatin, Pravastatin, Rosuvastatin: increases<br \/>\n            HMG-CoA reductase inhibitors concentration\n          <\/li>\n<\/ul>\n<\/li>\n<li class=\"bwlistitemmargb\">\n        Immunosuppressants<\/p>\n<ul>\n<li class=\"bwlistitemmargb\">\n            Cyclosporine: increases both cyclosporine and letermovir<br \/>\n            concentrations\n          <\/li>\n<li class=\"bwlistitemmargb\">\n            Sirolimus: increases sirolimus concentration\n          <\/li>\n<li class=\"bwlistitemmargb\">\n            Tacrolimus: increases tacrolimus concentration\n          <\/li>\n<\/ul>\n<\/li>\n<li class=\"bwlistitemmargb\">\n        Proton pump inhibitors<\/p>\n<ul>\n<li class=\"bwlistitemmargb\">\n            Omeprazole: decreases omeprazole concentration\n          <\/li>\n<li class=\"bwlistitemmargb\">\n            Pantoprazole: decreases pantoprazole concentration\n          <\/li>\n<\/ul>\n<\/li>\n<li class=\"bwlistitemmargb\">\n        CYP3A substrate examples<\/p>\n<ul>\n<li class=\"bwlistitemmargb\">\n            Alfentanil, fentanyl, midazolam and quinidine: may increase CYP3A<br \/>\n            substrate concentration\n          <\/li>\n<li class=\"bwlistitemmargb\">\n            Pimozide and ergot alkaloids are contraindicated\n          <\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<p>\n      The safety and efficacy of PREVYMIS (letermovir) in patients below 18<br \/>\n      years of age have not been established.\n    <\/p>\n<p>\n      For patients with creatinine clearance (CLcr) greater than 10 mL\/min (by<br \/>\n      Cockcroft-Gault equation), no dosage adjustment of PREVYMIS is required<br \/>\n      based on renal impairment. The safety of PREVYMIS in patients with<br \/>\n      end-stage renal disease (CLcr less than 10 mL\/min), including patients<br \/>\n      on dialysis, is unknown.\n    <\/p>\n<p>\n      No dosage adjustment of PREVYMIS is required based on mild (Child-Pugh<br \/>\n      Class A) to moderate (Child-Pugh Class B) hepatic impairment. PREVYMIS<br \/>\n      is not recommended for patients with severe (Child-Pugh Class C) hepatic<br \/>\n      impairment.\n    <\/p>\n<p>\n      <b>About PREVYMIS (letermovir)<\/b>\n    <\/p>\n<p>\n      PREVYMIS is a member of a new class of non-nucleoside CMV inhibitors<br \/>\n      (3,4 dihydro-quinazolines) and inhibits viral replication by<br \/>\n      specifically targeting the viral terminase complex. Cross resistance is<br \/>\n      not likely with drugs outside of this class. PREVYMIS is fully active<br \/>\n      against viral populations with substitutions conferring resistance to<br \/>\n      CMV DNA polymerase inhibitors. These DNA polymerase inhibitors are fully<br \/>\n      active against viral populations with substitutions conferring<br \/>\n      resistance to PREVYMIS. PREVYMIS has no activity against other viruses.<br \/>\n      Letermovir has been granted orphan designation for the prevention of CMV<br \/>\n      disease in at-risk populations in the U.S., EU and Japan.\n    <\/p>\n<p>\n      Under an agreement signed in 2012, Merck (through a subsidiary)<br \/>\n      purchased worldwide rights to develop and commercialize letermovir from<br \/>\n      AiCuris GmbH &amp; Co KG (<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.aicuris.com&amp;esheet=51725591&amp;newsitemid=20171206005351&amp;lan=en-US&amp;anchor=www.aicuris.com&amp;index=1&amp;md5=c80db8dac6b7a7be0f8e2502ff407ec3\" rel=\"nofollow\">www.aicuris.com<\/a>).\n    <\/p>\n<p>\n      <b>About Merck<\/b>\n    <\/p>\n<p>\n      For more than a century, Merck, a leading global biopharmaceutical<br \/>\n      company known as MSD outside of the United States and Canada, has been<br \/>\n      inventing for life, bringing forward medicines and vaccines for many of<br \/>\n      the world\u2019s most challenging diseases. Through our prescription<br \/>\n      medicines, vaccines, biologic therapies and animal health products, we<br \/>\n      work with customers and operate in more than 140 countries to deliver<br \/>\n      innovative health solutions. We also demonstrate our commitment to<br \/>\n      increasing access to health care through far-reaching policies, programs<br \/>\n      and partnerships. Today, Merck continues to be at the forefront of<br \/>\n      research to advance the prevention and treatment of diseases that<br \/>\n      threaten people and communities around the world &#8211; including cancer,<br \/>\n      cardio-metabolic diseases, emerging animal diseases, Alzheimer\u2019s disease<br \/>\n      and infectious diseases including HIV and Ebola. For more information,<br \/>\n      visit <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Findex.html&amp;esheet=51725591&amp;newsitemid=20171206005351&amp;lan=en-US&amp;anchor=vip2-msd.com\/merckcom-migrated&amp;index=2&amp;md5=6a389a3ac5d09a73011fe2f4031e6121\" rel=\"nofollow\">vip2-msd.com\/merckcom-migrated<\/a><br \/>\n      and connect with us on <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Ftwitter.com%2FMerck&amp;esheet=51725591&amp;newsitemid=20171206005351&amp;lan=en-US&amp;anchor=Twitter&amp;index=3&amp;md5=7fad8ec2340bc1cf83e5e6e732db52ce\" rel=\"nofollow\">Twitter<\/a>,<br \/>\n      <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.facebook.com%2FMerckInvents%2F&amp;esheet=51725591&amp;newsitemid=20171206005351&amp;lan=en-US&amp;anchor=Facebook&amp;index=4&amp;md5=0cd877c639727764fa6e47f5388093cb\" rel=\"nofollow\">Facebook<\/a>,<br \/>\n      <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.instagram.com%2Fmerck%2F&amp;esheet=51725591&amp;newsitemid=20171206005351&amp;lan=en-US&amp;anchor=Instagram&amp;index=5&amp;md5=66fe858b4696b33d96178f5d7c8adbe0\" rel=\"nofollow\">Instagram<\/a>,<br \/>\n      <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.youtube.com%2FMerck&amp;esheet=51725591&amp;newsitemid=20171206005351&amp;lan=en-US&amp;anchor=YouTube&amp;index=6&amp;md5=fd3082eea9785de8334ffc158c541f49\" rel=\"nofollow\">YouTube<\/a><br \/>\n      and <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.linkedin.com%2Fcompany%2Fmerck&amp;esheet=51725591&amp;newsitemid=20171206005351&amp;lan=en-US&amp;anchor=LinkedIn&amp;index=7&amp;md5=72ce8195f3d2e3a6df43b5f6d7cb2b31\" rel=\"nofollow\">LinkedIn<\/a>.\n    <\/p>\n<p>\n      <b>Forward-Looking Statement of Merck &amp; Co., Inc., Kenilworth, N.J.,<br \/>\n      U.S.A.<\/b>\n    <\/p>\n<p>\n      This news release of Merck &amp; Co., Inc., Kenilworth, N.J., USA (the<br \/>\n      \u201ccompany\u201d) includes \u201cforward-looking statements\u201d within the meaning of<br \/>\n      the safe harbor provisions of the U.S. Private Securities Litigation<br \/>\n      Reform Act of 1995. These statements are based upon the current beliefs<br \/>\n      and expectations of the company\u2019s management and are subject to<br \/>\n      significant risks and uncertainties. There can be no guarantees with<br \/>\n      respect to pipeline products that the products will receive the<br \/>\n      necessary regulatory approvals or that they will prove to be<br \/>\n      commercially successful. If underlying assumptions prove inaccurate or<br \/>\n      risks or uncertainties materialize, actual results may differ materially<br \/>\n      from those set forth in the forward-looking statements.\n    <\/p>\n<p>\n      Risks and uncertainties include but are not limited to, general industry<br \/>\n      conditions and competition; general economic factors, including interest<br \/>\n      rate and currency exchange rate fluctuations; the impact of<br \/>\n      pharmaceutical industry regulation and health care legislation in the<br \/>\n      United States and internationally; global trends toward health care cost<br \/>\n      containment; technological advances, new products and patents attained<br \/>\n      by competitors; challenges inherent in new product development,<br \/>\n      including obtaining regulatory approval; the company\u2019s ability to<br \/>\n      accurately predict future market conditions; manufacturing difficulties<br \/>\n      or delays; financial instability of international economies and<br \/>\n      sovereign risk; dependence on the effectiveness of the company\u2019s patents<br \/>\n      and other protections for innovative products; and the exposure to<br \/>\n      litigation, including patent litigation, and\/or regulatory actions.\n    <\/p>\n<p>\n      The company undertakes no obligation to publicly update any<br \/>\n      forward-looking statement, whether as a result of new information,<br \/>\n      future events or otherwise. Additional factors that could cause results<br \/>\n      to differ materially from those described in the forward-looking<br \/>\n      statements can be found in the company\u2019s 2016 Annual Report on Form 10-K<br \/>\n      and the company\u2019s other filings with the Securities and Exchange<br \/>\n      Commission (SEC) available at the SEC\u2019s Internet site (<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.sec.gov%2F&amp;esheet=51725591&amp;newsitemid=20171206005351&amp;lan=en-US&amp;anchor=www.sec.gov&amp;index=8&amp;md5=9bd7f82ee1f3dfdfa6a377aafb5c8c91\" rel=\"nofollow\">www.sec.gov<\/a>).\n    <\/p>\n<p>\n      <b>Please see Prescribing Information for PREVYMIS (letermovir) at <\/b><br \/>\n<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Fproduct%2Fusa%2Fpi_circulars%2Fp%2Fprevymis%2Fprevymis_pi.pdf&amp;esheet=51725591&amp;newsitemid=20171206005351&amp;lan=en-US&amp;anchor=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Fproduct%2Fusa%2Fpi_circulars%2Fp%2Fprevymis%2Fprevymis_pi.pdf&amp;index=9&amp;md5=dc40d4de990a40e316734274d2aab783\" rel=\"nofollow\">http:\/\/vip2-msd.com\/merckcom-migrated\/product\/usa\/pi_circulars\/p\/prevymis\/prevymis_pi.pdf<\/a><br \/>\n      <b>and Patient Information for PREVYMIS at <\/b><br \/>\n<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Fproduct%2Fusa%2Fpi_circulars%2Fp%2Fprevymis%2Fprevymis_ppi.pdf&amp;esheet=51725591&amp;newsitemid=20171206005351&amp;lan=en-US&amp;anchor=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Fproduct%2Fusa%2Fpi_circulars%2Fp%2Fprevymis%2Fprevymis_ppi.pdf&amp;index=10&amp;md5=edcc84d03921726eb66a3f1623b41078\" rel=\"nofollow\">http:\/\/vip2-msd.com\/merckcom-migrated\/product\/usa\/pi_circulars\/p\/prevymis\/prevymis_ppi.pdf<\/a>.\n    <\/p>\n<\/p>\n<p>\n<img decoding=\"async\" alt=\"\" src=\"\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20171206005351r2&amp;sid=hq1sc1&amp;distro=nx&amp;lang=en\" style=\"width:0;height:0\" \/><br \/>\n<span class=\"bwct31415\" \/><br \/>\n<\/span><\/p>\n<p>       Merck &amp; Co., Inc.<br \/>Media:<br \/>Pam Eisele, 267-305-3558<br \/>Robert        Consalvo, 908-740-6518<br \/>or<br \/>Investors:<br \/>Teri Loxam,        908-740-1986<br \/>Amy Klug, 908-740-1898     <\/p>\n","protected":false},"excerpt":{"rendered":"<p>Merck &amp; Co., Inc. (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the New England Journal of Medicine has published online the main results from the pivotal Phase 3 clinical study of PREVYMIS\u2122 (letermovir), the company\u2019s new medicine for prophylaxis (prevention) of cytomegalovirus (CMV) infection and disease in adult CMV-seropositive recipients [R+] of an allogeneic hematopoietic stem cell transplant (HSCT). The paper will also appear in a forthcoming print issue of the journal. CMV-seropositive patients who undergo allogeneic hematopoietic-cell transplantation are at high risk for CMV reactivation. CMV infection is a common clinically significant complication in these patients and early CMV reactivation after transplant is associated with increased mortality. PREVYMIS is a first-in-class antiviral drug that inhibits CMV replication. \u201cThis study culminates more than a decade of efforts to identify new, highly effective antiviral medicines for<\/p>\n","protected":false},"template":"","meta":{"_acf_changed":false,"bdl_company_name":[],"bdl_item_external_link":[],"inpsyde_pem_expiration_date":[],"inpsyde_pem_expiration_action":[],"footnotes":""},"tags":[53,64,289],"class_list":["post-745444","news_item","type-news_item","status-publish","hentry","tag-corporate-news","tag-latest-news","tag-press-release"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>New England Journal of Medicine Publishes Phase 3 Clinical Study of PREVYMIS\u2122 (letermovir), Merck\u2019s New CMV Prophylaxis Medicine - Merck.com<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/new-england-journal-of-medicine-publishes-phase-3-clinical-study-of-prevymis-letermovir-mercks-new-cmv-prophylaxis-medicine\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"New England Journal of Medicine Publishes Phase 3 Clinical Study of PREVYMIS\u2122 (letermovir), Merck\u2019s New CMV Prophylaxis Medicine - Merck.com\" \/>\n<meta property=\"og:description\" content=\"Merck &amp; Co., Inc. (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the New England Journal of Medicine has published online the main results from the pivotal Phase 3 clinical study of PREVYMIS\u2122 (letermovir), the company\u2019s new medicine for prophylaxis (prevention) of cytomegalovirus (CMV) infection and disease in adult CMV-seropositive recipients [R+] of an allogeneic hematopoietic stem cell transplant (HSCT). The paper will also appear in a forthcoming print issue of the journal. CMV-seropositive patients who undergo allogeneic hematopoietic-cell transplantation are at high risk for CMV reactivation. CMV infection is a common clinically significant complication in these patients and early CMV reactivation after transplant is associated with increased mortality. PREVYMIS is a first-in-class antiviral drug that inhibits CMV replication. \u201cThis study culminates more than a decade of efforts to identify new, highly effective antiviral medicines for\" \/>\n<meta property=\"og:url\" content=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/new-england-journal-of-medicine-publishes-phase-3-clinical-study-of-prevymis-letermovir-mercks-new-cmv-prophylaxis-medicine\/\" \/>\n<meta property=\"og:site_name\" content=\"Merck.com\" \/>\n<meta property=\"article:modified_time\" content=\"2025-11-07T06:26:07+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-content\/uploads\/sites\/152\/2022\/03\/Merck.png\" \/>\n\t<meta property=\"og:image:width\" content=\"3056\" \/>\n\t<meta property=\"og:image:height\" content=\"1380\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"9 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/new-england-journal-of-medicine-publishes-phase-3-clinical-study-of-prevymis-letermovir-mercks-new-cmv-prophylaxis-medicine\\\/\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/new-england-journal-of-medicine-publishes-phase-3-clinical-study-of-prevymis-letermovir-mercks-new-cmv-prophylaxis-medicine\\\/\",\"name\":\"New England Journal of Medicine Publishes Phase 3 Clinical Study of PREVYMIS\u2122 (letermovir), Merck\u2019s New CMV Prophylaxis Medicine - Merck.com\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\"},\"datePublished\":\"2017-12-06T17:02:00+00:00\",\"dateModified\":\"2025-11-07T06:26:07+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/new-england-journal-of-medicine-publishes-phase-3-clinical-study-of-prevymis-letermovir-mercks-new-cmv-prophylaxis-medicine\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/new-england-journal-of-medicine-publishes-phase-3-clinical-study-of-prevymis-letermovir-mercks-new-cmv-prophylaxis-medicine\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/new-england-journal-of-medicine-publishes-phase-3-clinical-study-of-prevymis-letermovir-mercks-new-cmv-prophylaxis-medicine\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"News\",\"item\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news-archive\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"New England Journal of Medicine Publishes Phase 3 Clinical Study of PREVYMIS\u2122 (letermovir), Merck\u2019s New CMV Prophylaxis Medicine\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/\",\"name\":\"Merck.com\",\"description\":\"Just another vip-msd.com site\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"New England Journal of Medicine Publishes Phase 3 Clinical Study of PREVYMIS\u2122 (letermovir), Merck\u2019s New CMV Prophylaxis Medicine - Merck.com","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/new-england-journal-of-medicine-publishes-phase-3-clinical-study-of-prevymis-letermovir-mercks-new-cmv-prophylaxis-medicine\/","og_locale":"en_US","og_type":"article","og_title":"New England Journal of Medicine Publishes Phase 3 Clinical Study of PREVYMIS\u2122 (letermovir), Merck\u2019s New CMV Prophylaxis Medicine - Merck.com","og_description":"Merck &amp; Co., Inc. (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the New England Journal of Medicine has published online the main results from the pivotal Phase 3 clinical study of PREVYMIS\u2122 (letermovir), the company\u2019s new medicine for prophylaxis (prevention) of cytomegalovirus (CMV) infection and disease in adult CMV-seropositive recipients [R+] of an allogeneic hematopoietic stem cell transplant (HSCT). The paper will also appear in a forthcoming print issue of the journal. CMV-seropositive patients who undergo allogeneic hematopoietic-cell transplantation are at high risk for CMV reactivation. CMV infection is a common clinically significant complication in these patients and early CMV reactivation after transplant is associated with increased mortality. PREVYMIS is a first-in-class antiviral drug that inhibits CMV replication. \u201cThis study culminates more than a decade of efforts to identify new, highly effective antiviral medicines for","og_url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/new-england-journal-of-medicine-publishes-phase-3-clinical-study-of-prevymis-letermovir-mercks-new-cmv-prophylaxis-medicine\/","og_site_name":"Merck.com","article_modified_time":"2025-11-07T06:26:07+00:00","og_image":[{"width":3056,"height":1380,"url":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-content\/uploads\/sites\/152\/2022\/03\/Merck.png","type":"image\/png"}],"twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"9 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/new-england-journal-of-medicine-publishes-phase-3-clinical-study-of-prevymis-letermovir-mercks-new-cmv-prophylaxis-medicine\/","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/new-england-journal-of-medicine-publishes-phase-3-clinical-study-of-prevymis-letermovir-mercks-new-cmv-prophylaxis-medicine\/","name":"New England Journal of Medicine Publishes Phase 3 Clinical Study of PREVYMIS\u2122 (letermovir), Merck\u2019s New CMV Prophylaxis Medicine - Merck.com","isPartOf":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website"},"datePublished":"2017-12-06T17:02:00+00:00","dateModified":"2025-11-07T06:26:07+00:00","breadcrumb":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/new-england-journal-of-medicine-publishes-phase-3-clinical-study-of-prevymis-letermovir-mercks-new-cmv-prophylaxis-medicine\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/vip2-msd.com\/merckcom-migrated\/news\/new-england-journal-of-medicine-publishes-phase-3-clinical-study-of-prevymis-letermovir-mercks-new-cmv-prophylaxis-medicine\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/new-england-journal-of-medicine-publishes-phase-3-clinical-study-of-prevymis-letermovir-mercks-new-cmv-prophylaxis-medicine\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"News","item":"https:\/\/vip2-msd.com\/merckcom-migrated\/news-archive\/"},{"@type":"ListItem","position":2,"name":"New England Journal of Medicine Publishes Phase 3 Clinical Study of PREVYMIS\u2122 (letermovir), Merck\u2019s New CMV Prophylaxis Medicine"}]},{"@type":"WebSite","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/","name":"Merck.com","description":"Just another vip-msd.com site","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/vip2-msd.com\/merckcom-migrated\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"acf":{"news_item_workflow_id":"01032370-fcf1-4aaa-bb9e-2e1cda48afba","news_item_aria_label":"","media_files":null,"document_path":"","file":""},"_links":{"self":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/745444","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item"}],"about":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/types\/news_item"}],"version-history":[{"count":1,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/745444\/revisions"}],"predecessor-version":[{"id":3674821,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/745444\/revisions\/3674821"}],"wp:attachment":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/media?parent=745444"}],"wp:term":[{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/tags?post=745444"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}